Birch pollen extract - Stallergenes Greer plc

Drug Profile

Birch pollen extract - Stallergenes Greer plc

Alternative Names: Bet v 1; Bet v 1a; Oralair Bet V 1 recombinant allergen; Oralair Birch; rBet v 1; Staller (Birch); Staloral Birch

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Stallergenes SA
  • Developer Endo International; Stallergenes Greer plc
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Seasonal allergic rhinitis

Most Recent Events

  • 14 Aug 2015 No recent reports on development identified - Phase-I for Seasonal allergic rhinitis in Canada (Sublingual)
  • 22 Jun 2015 Phase III development is ongoing in European Union
  • 14 Mar 2014 Efficacy & adverse events data from a phase IIIb trial in Seasonal allergic rhinitis released by Stallergenes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top